Cryoport, Inc. (NASDAQ:CYRX) Given Consensus Rating of “Hold” by Analysts

Cryoport, Inc. (NASDAQ:CYRX) has earned a consensus recommendation of “Hold” from the seven research firms that are currently covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $18.63.

Several brokerages have issued reports on CYRX. UBS Group raised their price target on Cryoport from $14.50 to $17.00 and gave the company a “neutral” rating in a report on Friday, March 15th. Jefferies Financial Group initiated coverage on shares of Cryoport in a report on Thursday, April 4th. They set a “buy” rating and a $21.00 target price for the company. Needham & Company LLC lowered their price target on shares of Cryoport from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, March 13th. Finally, Stephens restated an “equal weight” rating and set a $17.00 price objective on shares of Cryoport in a research report on Wednesday, March 13th.

Cryoport Stock Performance

Shares of CYRX stock opened at $16.38 on Friday. The firm has a market cap of $805.24 million, a PE ratio of -7.45 and a beta of 1.60. Cryoport has a 12 month low of $9.00 and a 12 month high of $24.17. The company’s fifty day simple moving average is $16.86 and its 200-day simple moving average is $14.93. The company has a quick ratio of 11.16, a current ratio of 11.73 and a debt-to-equity ratio of 0.82.

Cryoport (NASDAQ:CYRX) last announced its quarterly earnings data on Tuesday, March 12th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.19). The company had revenue of $57.26 million for the quarter, compared to the consensus estimate of $58.27 million. Cryoport had a negative return on equity of 11.86% and a negative net margin of 42.69%. Equities research analysts expect that Cryoport will post -1.31 EPS for the current fiscal year.

Insider Activity at Cryoport

In other news, Director Ramkumar Mandalam sold 3,217 shares of the stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $14.68, for a total value of $47,225.56. Following the completion of the sale, the director now directly owns 43,187 shares of the company’s stock, valued at $633,985.16. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, Director Ramkumar Mandalam sold 3,217 shares of the stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $14.68, for a total value of $47,225.56. Following the completion of the sale, the director now owns 43,187 shares in the company, valued at $633,985.16. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Jerrell Shelton sold 3,723 shares of the stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $16.35, for a total transaction of $60,871.05. Following the completion of the sale, the chief executive officer now owns 636,951 shares of the company’s stock, valued at approximately $10,414,148.85. The disclosure for this sale can be found here. In the last 90 days, insiders sold 73,940 shares of company stock valued at $1,147,538. 10.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Conestoga Capital Advisors LLC raised its stake in shares of Cryoport by 1.0% during the 1st quarter. Conestoga Capital Advisors LLC now owns 71,417 shares of the company’s stock valued at $1,264,000 after purchasing an additional 690 shares during the period. WCM Investment Management LLC increased its position in shares of Cryoport by 41.8% during the first quarter. WCM Investment Management LLC now owns 459,492 shares of the company’s stock valued at $8,133,000 after buying an additional 135,401 shares during the period. Allspring Global Investments Holdings LLC purchased a new stake in shares of Cryoport in the first quarter worth about $2,905,000. Sierra Summit Advisors LLC bought a new position in shares of Cryoport in the fourth quarter valued at approximately $665,000. Finally, Cadian Capital Management LP grew its stake in Cryoport by 30.4% during the fourth quarter. Cadian Capital Management LP now owns 3,464,079 shares of the company’s stock valued at $53,659,000 after acquiring an additional 807,340 shares in the last quarter. Institutional investors own 92.90% of the company’s stock.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.